<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064556</url>
  </required_header>
  <id_info>
    <org_study_id>144HPS13012</org_study_id>
    <nct_id>NCT02064556</nct_id>
  </id_info>
  <brief_title>CKD-330 Drug-Drug Interaction Study (Amlodipine)</brief_title>
  <acronym>CKD-330(A)</acronym>
  <official_title>A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of
      Amlodipine between free combination of Amlodipine and Candesartan and Amlodipine monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss of Amlodipine</measure>
    <time_frame>1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Amlodipine</measure>
    <time_frame>1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Amlodipine</measure>
    <time_frame>1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A(Amlodipine 10mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10mg 1T, PO, QD for 9days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(Amlodipine 10mg/Candesartan 32mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg</intervention_name>
    <description>Amlodipine 10mg 1T, PO, QD for 9days</description>
    <arm_group_label>B(Amlodipine 10mg/Candesartan 32mg)</arm_group_label>
    <other_name>Norvasc Tab. 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg/Candesartan 32mg</intervention_name>
    <description>Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days</description>
    <arm_group_label>A(Amlodipine 10mg)</arm_group_label>
    <other_name>Norvasc Tab. 10mg/Atacand Tab. 32mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer is between 20 and 45 years of age(inclusive) at the
             pre-study(screening).

          2. Volunteer who has 19kg/m² ≤ BMI(Body Mass Index) ≤ 26kg/m²

          3. When volunteer in screening, Must include under the items.

               1. 100 mmHg ≤ sitting SBP &lt;140 mmHg

               2. 60 mmHg ≤ sitting DBP &lt; 90 mmHg

               3. 45 bpm ≤ Pulse &lt; 95 bpm

          4. Those who decided to join the clinical trials by themselves and to comply with the
             precautions written consent.

        Exclusion Criteria:

          1. A previous history or present of clinically significant liver, renal,
             gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric,
             hemato-oncological, cardiovascular disease.

          2. Have a gastrointestinal disease history that can affect drug absorption(Crohn's
             disease, Ulcers, GERD, Gastritis, etc.) or surgery (except simple appendectomy or
             hernia surgery).

          3. The history of clinically significant hypersensitivity reaction about Investigational
             drugs and foods.

          4. The history of drug abuse or drug abuse showed a positive for urine drug test.

          5. Taking drugs have received any other investigational drug within 90 days prior to the
             first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within
             30 days prior to the first dosing.

          6. Whole blood donation within 60 days prior to the first dosing or plasma donation
             within 30 days prior to the first dosing.

          7. Taking drugs that clinical trials expected to affect within 14days or taking food
             containing caffeine, grapefruit within 7days before the first dosing.

          8. A heavy alcohol consumer(alcohol&gt;3cup/day or 3times/week within last 1month)

          9. A heavy smoker(cigarette&gt;10cigarettes/day)

         10. The subject has positive results of serum tests(Hepatitis B, C, HIV Test, Syphilis).

         11. Have the Liver enzyme levels(AST, ALT) or Bilirubin, total results greater than 1.5
             times the UNL.

         12. Have the result of Creatinine clearance is less than 80mL/min(Cockcroft-Gault equation
             applicable).

         13. The result of 12-lead ECG in screening test is QTc&gt;450msec.

         14. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

